Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013747 | 0.87 | HTT (0.72) | PKMALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL22764320 | 0.84 | HTT (0.66) | ALDH1A1HTTSMN1; SMN2NPSR1TSHR | |
| SCHEMBL7121916 | 0.82 | SMN1; SMN2 (0.77) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL3996738 | 0.81 | TSHR (0.73) | ALDH1A1TP53GAASMN1; SMN2TSHR | |
| SCHEMBL12569441 | 0.81 | PKM (0.60) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL3758627 | 0.80 | ALDH1A1 (0.63) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL29956307 | 0.80 | ALDH1A1 (0.63) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL25077827 | 0.79 | PKM (0.58) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL14688615 | 0.79 | HTT (0.58) | PKMALDH1A1TP53HTTGAA | |
| SCHEMBL27752641 | 0.79 | PKM (0.58) | PKMALDH1A1TP53HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325885-B2 | Method for treating stomach cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-10 | — | — | US | disclosed |
| US-11312680-B2 | Method for treating a patient having a colon cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11214537-B2 | Method for making anti-cancer compounds | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-23 | — | — | US | disclosed |
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-09 | — | — | US | disclosed |
| US-20210340097-A1 | METHOD FOR MAKING ANTI-CANCER COMPOUNDS | KING ABDULAZIZ UNIVERSITY (SA) | 2021-11-04 | — | — | US | disclosed |
| US-11136288-B2 | Method for treating a patient having cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-05 | — | — | US | disclosed |
| US-20210188765-A1 | METHOD FOR TREATING A PATIENT HAVING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-06-24 | — | — | US | disclosed |
| US-10988439-B2 | Cytotoxic compounds, pharmaceutical compositions thereof, and methods of treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-04-27 | — | — | US | disclosed |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2020-12-10 | — | — | US | disclosed |
| US-10844007-B1 | Amide group-containing compounds and use for cancer treatment | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | TUBB, TUBB1, TUBA1C | PKM 1216/4885ALDH1A1 3409/4885TP53 227/4885 |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | TUBB1, TUBA1C, TUBB | PKM 1104/4885ALDH1A1 2594/4885TP53 192/4885 |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | SRC, MCL1, LYN | PKM 891/4885ALDH1A1 3413/4885TP53 33/4885 |
| US-10988439-B2 | Cytotoxic compounds, pharmaceutical compositions thereof, and methods of treating cancer | SRC, MCL1, LYN | PKM 891/4885ALDH1A1 3413/4885TP53 33/4885 |
| US-11214537-B2 | Method for making anti-cancer compounds | MCL1, TUBB, TUBB1 | PKM 1511/4885ALDH1A1 3075/4885TP53 137/4885 |
| US-20210340097-A1 | METHOD FOR MAKING ANTI-CANCER COMPOUNDS | MCL1, TUBB, TUBB1 | PKM 1511/4885ALDH1A1 3075/4885TP53 137/4885 |
| US-20210188765-A1 | METHOD FOR TREATING A PATIENT HAVING CANCER | TUBA1C, TUBB1, TUBB | PKM 1238/4885ALDH1A1 1926/4885TP53 112/4885 |
| US-11312680-B2 | Method for treating a patient having a colon cancer | TUBB1, TUBA1C, TUBB | PKM 1104/4885ALDH1A1 2594/4885TP53 192/4885 |
| US-10844007-B1 | Amide group-containing compounds and use for cancer treatment | SRC, TUBB, TUBB1 | PKM 1373/4885ALDH1A1 3615/4885TP53 211/4885 |
| US-11325885-B2 | Method for treating stomach cancer | TUBB, TUBB1, TUBA1C | PKM 1216/4885ALDH1A1 3409/4885TP53 227/4885 |
| US-11136288-B2 | Method for treating a patient having cancer | TUBA1C, TUBB1, TUBB | PKM 1238/4885ALDH1A1 1926/4885TP53 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.